Cosmetic cross-reference

Allantoin

CAS 97-59-6

Allantoin (CAS 97-59-6) is a Phase 2 pharmaceutical compound with 4 bioactivity targets and 66 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Allantoin

CAS Number

97-59-6

UNII

344S277G0Z

InChIKey

POJWUDADGALRAB-UHFFFAOYSA-N

ChEMBL ID

CHEMBL593429

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL593429 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	GI50	98433.2985 nM	60	-
-	Potency	22949.340000000004 nM	5	-
-	IC50	13484.206666666665 nM	2	-
-	AC50	39810.7 nM	1	-

SOURCE DrugCentral 2023 / FAERS disproportionality 66 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Methaemoglobinaemia	114	445.284	10027496
Macular degeneration	124	311.115	10025409
Appendicolith	59	174.364	10074458
Blood phosphorus increased	60	163.712	10050196
Appendicitis	60	120.008	10003011
Ventricular fibrillation	64	108.476	10047290
Cardiogenic shock	60	84.716	10007625
Ascites	75	74.188	10003445
Product complaint	40	73.434	10069902
Myasthenia gravis	33	68.764	10028417
Blood uric acid increased	35	65.915	10005861
Abdominal distension	88	64.994	10000060
Creatinine renal clearance decreased	38	63.744	10011372
Stress	70	60.974	10042209
Sedation complication	34	60.045	10079741
Multiple organ dysfunction syndrome	79	56.19	10077361
Blood calcium decreased	43	54.379	10005395
Hyponatraemia	94	52.958	10021036
Dry mouth	69	52.154	10013781
Abdominal pain	153	48.492	10000081
Sedation	50	47.893	10039897
Depressed level of consciousness	59	40.393	10012373
Analgesic therapy	11	36.714	10053469
Sleep disorder therapy	11	36.49	10040990
Hyperphosphataemia	18	36.125	10020711
Orthostatic hypotension	43	35.094	10031127
Cyanosis	30	35.031	10011703
Drug therapy	11	34.735	10063370
Vomiting	205	34.32	10047700
Sepsis	108	33.015	10040047
Aspartate aminotransferase increased	66	30.741	10003481
Alopecia	8	28.411	10001760
Constipation	109	27.86	10010774
Fatigue	85	26.637	10016256
Nausea	258	25.781	10028813
Iron deficiency	18	25.3	10022970
Somnolence	91	24.478	10041349
Product dose omission issue	8	24.426	10084406
Peripheral swelling	8	24.233	10048959
Cognitive disorder	41	22.636	10057668
Incorrect route of product administration	29	21.824	10081202
Alanine aminotransferase increased	64	21.681	10001551
Arthralgia	44	21.337	10003239
Joint swelling	14	21.164	10023232
Bacterial infection	26	20.119	10060945
Synovitis	3	19.025	10042868
Arthropathy	7	18.698	10003285
Haemolysis	16	18.485	10018910
Intentional product use issue	4	18.425	10076308
Hypophosphataemia	19	18.386	10021058

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE RxNorm drug names 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
ALLANTOIN	508	SU	MTHSPL
Allantoin	508	SU	MTHSPL
allantoin	508	SU	MTHSPL
allantoin	508	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Allantoin used for in pharmaceutical contexts?

Allantoin (CAS 97-59-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Allantoin?

Allantoin has 66 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Methaemoglobinaemia, Macular degeneration, Appendicolith, Blood phosphorus increased, Appendicitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Allantoin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Allantoin with EU status "permitted".

What clinical phase is Allantoin in?

Allantoin is rendered with ChEMBL max phase 2.